



Optimization of *RfxCas13d* Expression in *Escherichia coli* Host using Response Surface Methodology

Sepideh Abbaszadeh ^{1,2}, Shahin Eghbalsaied ², Meysam Soleimani ³, Sadegh Khazalpour ⁴
and Saeid Afshar ^{1,5*}

1. Department of Medical Biotechnology, School of Advanced Medical Sciences and Technologies, Hamadan University of Medical Sciences, Hamadan, Iran
2. Research Center for Molecular Medicine, Institute of Cancer, Hamadan University of Medical Sciences, Hamadan, Iran
3. Department of Pharmaceutical Biotechnology, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran
4. Department of Analytical Chemistry, Faculty of Chemistry and Petroleum Science, Bu-Ali Sina University, Hamadan, Iran
5. Cancer Research Center, Institute of Cancer, Hamadan University of Medical Sciences, Hamadan, Iran

Abstract

Background: RfxCas13d, a key member of the Cas13 family, plays a vital role in CRISPR-based diagnostics for RNA sequence detection and gene silencing. This study aimed to enhance *RfxCas13d* expression by optimizing key parameters using Response Surface Methodology (RSM).

Methods: The plasmid pET28b-RfxCas13d-His (Addgene 141322) was introduced into BL21 (DE3) and RosettaTM (DE3) strains. Initial expression tests were conducted, followed by RSM-guided optimization of factors such as isopropyl β-D-1-thiogalactopyranoside (IPTG) concentration, temperature, cell density at induction, and induction time in BL21 (DE3). Protein expression levels were quantified using ImageJ and AlphaEaseFC software to analyze band intensities.

Results: BL21 (DE3) was selected for further optimization based on preliminary results. Analysis of 26 RSM-designed experiments revealed that temperature, induction time, IPTG concentration, and their interactions significantly influenced *RfxCas13d* expression. Optimal conditions were identified as 0.25 mM IPTG, an OD_{600 nm} of 0.8 at induction, 37°C, and Overnight (ON) of induction. The regression model exhibited high accuracy, with a correlation coefficient of 0.97 and a p-value less than 0.05, confirming a strong linear relationship between predicted and observed values.

Conclusion: This study highlights the significant impact of the four optimized factors on *RfxCas13d* expression. Under optimized conditions, a soluble protein concentration of 3.6 mg/100 ml cell culture was achieved after purification. It represents the first application of RSM for optimizing *RfxCas13d* expression, providing a foundation for further refinement of expression conditions. Continued use of RSM in future research will enhance the efficiency of RfxCas13d production for diagnostic and therapeutic applications.

Keywords: Base sequence, CRISPR-associated proteins, *Escherichia coli*, Protein biosynthesis

To cite this article: Abbaszadeh S, Eghbalsaied Sh, Soleimani M, Khazalpour S, Afshar S. Optimization of *RfxCas13d* Expression in *Escherichia coli* Host using Response Surface Methodology. Avicenna J Med Biotech 2025;17(2):122-130.

* **Corresponding author:**
Saeid Afshar, Ph.D., Department
of Medical Biotechnology, School
of Advanced Medical Sciences and
Technologies, Hamadan
University of Medical Sciences,
Hamadan, Iran
Tel: +98 81 38381796
Fax: +98 81 38380208
E-mail:
safsharh@gmail.com
Received: 4 Sept 2024
Accepted: 4 Mar 2025

Introduction

The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated (Cas) system was initially discovered as an adaptive immune mechanism in bacteria and archaea, enabling them to

recognize and eliminate invading foreign genetic elements ¹. In 2012, a groundbreaking discovery revealed that Cas9 protein, when combined with single-guide RNA (sgRNA), could precisely target and cleave spe-

cific DNA sequences *in vitro* ², This finding established CRISPR-Cas9 as a revolutionary tool for gene editing ^{3,4}. By 2016, the CRISPR-Cas9 system had been adapted for nucleic acid detection, further expanding its applications ⁵. The discovery of new CRISPR-Cas systems has considerably advanced nucleic acid recognition ⁶. Notably, the introduction of CRISPR-Cas12 and CRISPR-Cas13 into nucleic acid recognition frameworks has proven pivotal, leveraging their trans-cleaving mechanisms. These systems exhibit high detection accuracy and efficiency by identifying specific DNA and RNA targets, respectively, and triggering single-stranded DNA (ssDNA)/RNA trans-cleavage upon target recognition and cleavage ^{7,8}. The Cas13 protein family is distinguished by two specific HEPN ribonuclease motifs that become active when they bind to target RNA, guided by gRNA ⁹. This family includes four known subtypes: Cas13a (C2c2), Cas13b, Cas13c, and Cas13d, with Cas13d being the smallest and most efficient for RNA targeting ^{10,11}. Cas13-based systems have been widely employed in biosensor development, including the SHERLOCK technique and electrochemical biosensors, due to their high specificity and sensitivity ^{8,12,13}. Among these, RfxCas13d distinguishes itself through its compact size, high specificity, and minimal off-target activity, establishing it as a leading tool for RNA targeting and editing. Its exceptional efficiency in mammalian cells further amplifies its potential for therapeutic and diagnostic applications. These attributes make RfxCas13d a highly adaptable and effective choice for RNA-based interventions, setting it apart from other Cas13 ^{14,15}. Given that numerous studies highlight the critical roles of oncogene transcription products and the overexpression of various non-coding RNAs, such as LncRNAs, in cancer development and progression, the distinct features of RfxCas13d make it a promising and versatile tool for driving future research advancements in this area ^{17,18}.

For optimal recombinant protein production, it is crucial to optimize culture conditions like temperature, cell density at induction, and isopropyl β -D-1-thiogalactopyranoside (IPTG) concentration ¹⁹. The traditional One-Factor-at-a-Time (OFAT) method requires numerous experiments to find optimal conditions, but is often inefficient and fails to reveal interactions between variables ²⁰. In contrast, the Design of Experiments (DoE) approach offers by identifying key factors and their interactions, leading to better predictions of optimal conditions with fewer trials ²¹. RSM within DoE has been successfully used to maximize recombinant protein yields by modeling the effects of various variables and their interactions ^{22,23}. In RSM, two widely used experimental designs include the Box-Behnken Design (BBD) and the Central Composite Design (CCD) ²⁴. Many studies have optimized both upstream and downstream processes using the RSM-Box-Behnken approach ²⁵⁻²⁸.

In this particular study, the RSM-Box-Behnken design was applied to optimize culture conditions for enhancing the total expression of Cas13. Four parameters- temperature, cell density at induction, IPTG concentration, and induction time-were analyzed for their individual and combined effects on protein expression.

Materials and Methods

Bacterial cultivation was carried out using Luria-Bertani (LB) medium (Qlab, Canada). The *Escherichia coli* (*E. coli*) strains BL21(DE3) and Rosetta™(DE3) were obtained from the biobank of Hamadan University of Medical Sciences (Hamadan, Iran). For recombinant protein expression, the plasmid pET28b-RfxCas13d-His (Addgene plasmid #141322) was utilized. Antibiotics, including kanamycin and chloramphenicol, were purchased from Sigma-Aldrich (Germany). Additionally, a pre-stained protein marker (10-180 kDa, Cat. No. E-BC-R273) was acquired for protein analysis.

The bacterial strain and vector

pET28b-RfxCas13d-His system (Addgene 141322) includes the recombinant sequence of human RfxCas13d. This plasmid also features a kanamycin resistance gene and uses the T7 promoter, regulated by the lac promoter sequence, to drive the expression of RfxCas13d. The human-derived RfxCas13d sequence was expressed in both *E. coli* strains BL21 (DE3) and Rosetta™(DE3), which served as host cells harboring the recombinant plasmid for RfxCas13d protein production. The plasmid was successfully transformed into competent cells prepared using a cold calcium chloride solution, following the heat shock method as described by Sambrook *et al* ²⁹. Selection of transformants occurred on LB agar plates supplemented with 50 μ g/ml kanamycin for BL21 (DE3), 50 μ g/ml kanamycin and 15 μ g/ml chloramphenicol for Rosetta™(DE3), followed by cultivation in LB broth for 18 hr, and bacterial suspensions were stored in 25% (v/v) glycerol at -80°C for future use.

Initial expression analysis

For initial expression analysis, "Overnight (ON)" cultures of BL21 (DE3) and Rosetta™(DE3) containing the plasmid were diluted 1:100 into 5 ml of fresh culture media. These cultures were then incubated at 37°C while they were shaken until the Optical Density (OD) 600 reached 0.5. Subsequently, 1 ml of each culture was centrifuged, and the resulting cell pellets were stored at -20°C for later analysis. The remaining culture had IPTG (Sigma-Aldrich, Germany) added to a final concentration of 0.5 mM and was further incubated with shaking at 37°C for 3 hr and ON. For protein expression analysis, 1 ml samples from these cultures were centrifuged to collect the cells, which were then analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) using a gel consisting of a 10% separating gel and a 5% stacking gel. Finally,

The SDS-PAGE of separated proteins was visualized through staining with Coomassie Brilliant Blue.

Western blot

Western blot analysis involved the electro-transfer of proteins onto Amersham Protran 0.2 NC nitrocellulose Western blotting membranes at a setting of 30 mA for 14 hr, following the modified protocol provided by Sambrook *et al*²⁹. The membranes were blocked for 3 hr in Tris-Buffered Saline-Tween (TBST) containing 3% nonfat milk, washed three times with TBST, and incubated for 3 hr with Mouse Anti-His Tag HRP-conjugated Monoclonal Antibody (Catalog #MAB-050H, 1:4000). The protein band was detected using an ECL kit (Catalog #:B111420, PARS Co. Mashhad, IR Iran) using FUSION FX chemiluminescence and fluorescence imaging.

Experiment designs

The factorial RSM-BBD methodology was employed to examine the effects of four independent variables including induction temperature, IPTG concen-

tration, cell density at induction, and post-induction time (3 hr and ON), on RfxCas13d protein expression. The levels tested for each factor are presented in table 1. This analysis utilized Minitab 17 software to conduct 26 experimental runs. Statistical analysis through ANOVA³⁰ was applied to determine significant variables impacting protein expression. Expression levels of RfxCas13d in all experiments were quantified using high-quality images captured from SDS-PAGE gel evaluated with AlphaEaseFC and ImageJ software.

Purification of the soluble portion of recombinant rfxcas-13d

For purification, the soluble fraction of the recombinant rfxcas13d from a 100 ml culture under optimal conditions was resuspended in 25 ml of Lysis buffer (50 mM NaH₂PO₄, 300 mM NaCl, 10% v/v glycerol, 20 mM βME, pH=8.0) and maintained at 4°C. The cells were then sonicated for 20 min at 80% amplitude with intervals of 30 s on and 60 s off using bandelin sonopuls homogeniser while being maintained on ice. Fol-

Table 1. Displays factor values and responses according to the Box-Behnken experimental design

Runorder	Stdorder	Pttype	Blocks	#O*10	#Te	#I	#Ti	Response	Predict
1	1	2	1	5	16	625	3 h	3.502627	3.456219
2	9	2	1	6.5	16	250	3 h	3.327496	3.669004
3	5	2	1	5	26.5	250	3 h	3.502627	3.423109
4	21	2	1	8	26.5	1000	ON	5.604203	5.615502
5	3	2	1	5	37	625	3 h	2.364273	2.606998
6	8	2	1	8	26.5	1000	3 h	2.451839	2.447629
7	2	2	1	6.5	16	625	3 h	3.415061	2.382451
8	13	0	1	6.5	26.5	625	3 h	2.014011	3.017254
9	19	2	1	8	26.5	250	ON	7.005254	7.016553
10	7	2	1	5	26.5	1000	3 h	4.640981	4.67092
11	18	2	1	5	26.5	250	ON	2.714536	2.528812
12	16	2	1	5	37	625	ON	1.926445	2.251584
13	20	2	1	5	26.5	1000	ON	3.502627	3.360686
14	22	2	1	6.5	16	250	ON	3.765324	4.266908
15	4	2	1	8	37	625	3 h	2.977233	3.285632
16	10	2	1	6.5	37	250	3 h	3.940455	3.598241
17	11	2	1	6.5	16	1000	3 h	2.451839	2.793347
18	17	2	1	8	37	625	ON	7.267951	7.408326
19	25	2	1	6.5	37	1000	ON	6.392294	6.412267
20	14	2	1	5	16	625	ON	1.751313	1.6071
21	23	2	1	6.5	37	250	ON	5.779335	5.68985
22	15	2	1	8	16	625	ON	3.502627	3.192915
23	12	2	1	6.5	37	1000	3 h	5.341506	4.736595
24	6	2	1	8	26.5	250	3 h	3.590193	3.432742
25	24	2	1	6.5	16	1000	ON	2.62697	2.975314
26	26	0	1	6.5	26.5	625	ON	4.640981	4.154042

#I (IPTG Concentration), Te (Temperature), O (Od600 nm before induction), and Ti (post-induction time).

lowing sonication, the lysate was centrifuged at 12,000 *rpm* for 25 *min*, and the pellet was removed and discarded. The supernatant was then purified using Ni-NTA agarose affinity chromatography under native conditions, following the manufacturer's protocol (DNAbiotech, Iran). The column was washed with buffers containing 20 *mM* imidazole, and subsequently, the RfxCas13d protein was eluted using 250 *mM* imidazole. The quantification of the concentration of the purified protein was performed using the Bradford assay method and Bovine Serum Albumin (BSA) (Sigma-Aldrich) was utilized to prepare the standard curve³¹.

Results

Initial expression analysis

Initially, the recombinant protein's authenticity was confirmed through Western blot analysis, where the specific protein band's location was identified (Figure 1A). Furthermore, the protein expression was analyzed at two distinct intervals, 3 *hr* and ON, within BL21 (DE3) and Rosetta™ (DE3) strains. This assessment involved visual inspection of the protein bands on an electrophoresis gel, revealing no significant differences in protein expression between the two strains (Figure 1B). However, the presence of additional protein bands was significantly higher in the Rosetta™ (DE3) strain compared to the BL21 (DE3) strain, which could increase the complexity of downstream purification due to the presence of additional protein bands. Consequently, protein expression was fine-tuned specifically for the BL21 (DE3) strain.

Optimization of recombinant RfxCas13d expression

The RSM-BBD approach was employed to evaluate the effects of four variables- temperature of induction, IPTG concentration, cell density at induction, and post-induction time- on *RfxCas13d* expression. A four-level




Figure 1. A) Displays the results of a Western blot analysis for the RfxCas13d protein. The recombinant RfxCas13d protein has a molecular weight of 113 kilodaltons, which aligns with the band observed in the Western blot. B) Provides a preliminary evaluation of protein expression in BL21 (DE3) and Rosetta™ (DE3) strains. Columns 1 and 2 represent expression in Rosetta™ (DE3) at 3 *hr* and ON post-induction, respectively, while columns 4 and 5 show expression in BL21™ (DE3) at the same time points. Protein expression levels showed no notable difference between the two strains.




Figure 2. Displays *RfxCas13d* expression in SDS-PAGE under 26 different cultivation conditions as designed by RSM. Lane M features a protein marker, while other lanes represent various experimental conditions. Turbidity values for these experiments were calculated using AlphaEaseFC software.

BBD incorporating 26 experimental runs was adopted. The expression levels of RfxCas13d across all trials were quantified through images obtained from SDS-PAGE gels and AlphaEaseFC software (Figure 2). The outcomes derived from these BBD experiments regarding *RfxCas13d* expression are summarized in table 1. Quadratic regression models for optimizing *RfxCas13d* expression were validated and confirmed through Analysis of Variance (ANOVA), with a p-value below 0.05 indicating statistical significance. ANOVA highlighted the model's significant impact on *RfxCas13d* expression (p-value <0.05) (Table 2). The normal probability plot illustrates the normal distribution of the residuals. In the Versus Fits Plot and the Versus Order Plot, the residuals exhibit random scatter, indicating that the model is well-fitted (Figures 3A-C). Validation tests corroborated that the experimentally obtained production values closely matched those predicted statistically, thereby verifying the model's accuracy. Figure 3D displayed a correlation of 0.97 and a p-value <0.05, suggesting a strong linear relationship between observed and predicted values.

Regarding the total protein production of RfxCas13d, ANOVA revealed significant model terms including Te, I, Ti, I², Te*Ti, Te*I, O*I, O*Te, and O*Ti, while other terms were not significant due to p-values exceeding 0.05, leading to their exclusion (Table 2). Consequently, a simplified second-order polynomial equation was formulated for protein expression (response) based on significant factors, represented as I (IPTG concentration), Te (temperature), O (OD600 *nm* before induction), and Ti (post-induction time) (Equation).

Time and the interaction between OD600 *nm* before induction and time were identified as having the most substantial influence on the response. These were followed by temperature, the interaction of OD600 *nm* before induction with temperature, the square of IPTG concentration, as well as the interactions between temperature and time, IPTG concentration and OD600 *nm* before induction, and IPTG concentration (Figure 4). The interaction effects between these independent variables were further explored through three-dimensional response surface graphs (Figure 5).

Optimization of RfxCas13d in *E. coli*

Table 2. Investigation of variance (ANOVA) for the full quadratic model concerning RfxCas13d production is detailed

Source	Degrees of freedom	Adjusted sum of squares	Adjusted mean squares	F-value	p-value
Model	13	56.6506	4.3577	13.43	0
Linear	4	23.2495	5.8124	17.92	0
#O	1	0.6314	0.6314	1.95	0.188
#Te	1	5.1733	5.1733	15.95	0.002
#I	1	2.4958	2.4958	7.69	0.017
#Ti	1	17.9575	17.9575	55.36	0
Square	3	6.253	2.0843	6.43	0.008
O*O	1	0.6401	0.6401	1.97	0.185
Te*Te	1	0.1223	0.1223	0.38	0.551
I*I	1	3.534	3.534	10.89	0.006
2-Way Interaction	6	29.5799	4.93	15.2	0
O*Te	1	5.0975	5.0975	15.71	0.002
O*I	1	2.493	2.493	7.68	0.017
O*Ti	1	17.8192	17.8192	54.93	0
O*I	1	2.0281	2.0281	6.25	0.028
Te*Ti	1	2.1402	2.1402	6.6	0.025
I*Ti	1	0.173	0.173	0.53	0.479
Error	12	3.8928	0.3244		
Total	25	60.5434	-	-	-

I (IPTG concentration), Te (Temperature), O (OD600 nm before induction), and Ti (post-induction time).




Figure 3. Diagnostic Plots for the Quadratic Models. A) Normal Probability Plot: This plot demonstrates that the residuals—the differences between observed and predicted values—are normally distributed. The alignment of points along the reference line supports the assumption of normality. B) Versus Fits Plot: This plot exhibits an ideal pattern, with residuals randomly dispersed around zero. The absence of any systematic trends or patterns indicates that the model fits the data well. C) Versus Order Plot: This plot was used to detect any time-dependent patterns or autocorrelation. The random scattering of residuals suggests no issues related to the order of observations. D) Matrix Plot of Response and Predictors: This plot presents a strong correlation matrix between the response variable and the predictors. It highlights the relationships and dependencies among the variables, indicating a well-structured model.

Time= Ti	Equation
3 hr	Response = 6.28–0.00431 I–0.324 Te+0.000006 I*I+0.0567 O*Te–0.000992 O*I+0.000128 Te*I
ON	Response = -3.83–0.00486 I–0.253 Te+0.000006 I*I+0.0567 O*Te–0.000992 O*I+0.000128 Te*I

The range of recombinant protein expression levels varied widely across the 26 designed experiments,

from 1.75 to 7.27% turbidity as shown in table 1. Following the identification of optimal conditions (IPTG




Figure 4. Evaluation of the effect of the significant parameters on *RfxCas13d* expression, calculated by the sum of squares index. I (IPTG concentration), Te (temperature), O (OD600 nm before induction), and Ti (post-induction time).

concentration=250 μ M, temperature=37°C, OD600 nm before induction=0.8, and post-induction time at ON), recombinant RfxCas13d protein expression was executed and subsequently characterized by SDS-PAGE, as depicted in figure 6A. This characterization aimed to assess the model's suitability. The experimental outcome was then compared with data from the optimum point and predictive protein levels. The numerical equivalent of the predicted turbidity and the experimental result were calculated with Image J and AlphaEaseFC software, which were 8.45 and 8.2, respectively.

Protein purification

Initial tests on the expression of RfxCas13d recombinant protein under optimal conditions indicated that half of the protein was found in the soluble phase. The recombinant RfxCas13d protein was then successfully fractionated using a Ni-NTA affinity chromatography column (Figure 6B) and quantified using the Bradford assay. A concentration of 3.6 mg/100 ml cell culture of the soluble protein was achieved under these optimal conditions.




Figure 5. A three-dimensional response surface illustrates the expression of RfxCas13d. This figure examines the impact of two variables while maintaining the other two at zero levels. I (IPTG concentration), Te (temperature), O (OD600 nm before induction), and Ti (post-induction time).




Figure 6. A) SDS-PAGE under optimal cultivation conditions is shown, induced (I), uninduced (UI), and protein molecular weight marker (M). B) RfxCas13d purification using a Ni-NTA column is shown, with eluted protein fractions (E1, E2, and E3), wash (W), flow-through (FT), before column (BC) and protein molecular weight marker (M).

Discussion

RfxCas13d, also referred to as CasRx is a prominent member of the Cas13 family known for its ability to degrade lateral transcripts when targeting both abundant reporter RNAs and native RNAs. This characteristic has facilitated the use of the Cas13 family in detection of specific RNA transcripts. Techniques such as SHERLOCK have been developed utilizing this capability^{12,13}. Additionally, techniques like microinjection involving gRNA and the purified RfxCas13d protein into animal embryos have proven effective in silencing particular transcripts³². The pET28b-RfxCas13d-His system (Addgene #141322) was used for expression. This system includes a kanamycin resistance gene and utilizes the T7 promoter, regulated by the lac promoter sequence, to drive *RfxCas13d* expression. The RfxCas13d segment of this plasmid originates from pT3TS-RfxCas13d, and the humanized RfxCas13d sequence may influence its bacterial expression" for clarity and conciseness³³. The distinct advantage of this bacterial expression plasmid over others containing RfxCas13d is its lack of a fusion partner sequence, allowing for post-expression purification through immobilized metal affinity chromatography. Previous research selected bacterial expression plasmids with the humanized

RfxCas13d sequence from the Rosetta™ strain for expressing RfxCas13d³³. Rosetta™ host strains, which are derivatives of BL21, are engineered to boost the expression of eukaryotic proteins featuring infrequently used codons in *E. coli*. These strains carry tRNAs for AGG, AGA, CCC, CUA, AUA, and GGA codons on a chloramphenicol-resistant plasmid, facilitating a more universal translation that might be confined by *E. coli* codon usage³⁴. Nevertheless, protein expression remains an empirical process, and studies have demonstrated successful expression in BL21 strains of proteins containing rare codons³⁵. In this investigation, the pET28b-RfxCas13d-His plasmid was transformed into both strains, and initial observations of RfxCas13d protein expression were made. The visual findings indicated no significant differences in the target protein between the two strains. However, due to excessive non-target protein bands in the Rosetta strain, the BL21 strain was chosen for further exploration to refine expression using the RSM. In this study, we employed an RSM approach to examine how variations in IPTG concentration, temperature, OD600 nm before induction, and post-induction time impact the efficiency of *RfxCas13d* expression.

The ideal conditions for producing recombinant proteins are affected by multiple factors. It is important to recognize that the overexpression of proteins using plasmid DNA can impose a metabolic load, potentially disrupting growth rates and diminishing biomass accumulation. Such disturbances may lead to instability in plasmid DNA. The maximum specific growth rate is capped by the commencement of glucose overflow metabolism and the production of acetate, both of which negatively impact recombinant protein production. Consequently, it becomes crucial to establish optimal expression conditions. In this context, RSM stands out as a highly precise multivariate analysis technique capable of altering multiple parameters simultaneously³⁶⁻³⁸. Critical factors identified for efficient recombinant protein production that require optimization, including IPTG concentration, induction timing, cell density, and temperature. Lowering IPTG concentrations can moderate transcription rates and enhance the production of soluble proteins. Typically, IPTG concentrations range from 0.1 to 1.0 mM for inducing protein expression, but reducing these concentrations further can influence solubility³⁹. Determining the optimal OD for induction is essential for maximizing expression levels. It is also noted that extending the incubation period post-induction does not invariably lead to increased expression levels. Over extended culture periods, proteases may degrade heterologously expressed proteins. Thus, optimizing expression duration minimizes degradation and reduces costs⁴⁰.

Traditionally, adjusting one variable at a time while holding others constant has been the approach to optimize protein expression, though this method necessitates numerous experiments and may result in misin-

terpreted interactions between variables. RSM offers a robust alternative to address these challenges. In the present study, the significance of the mathematical model was confirmed with a low p-value (less than 0.05). Validation tests comparing experimental outcomes with predictions from the model demonstrated a strong linear correlation, evidenced by a correlation coefficient of 0.97 and a p-value <0.05.

ANOVA results highlighted significant model terms such as Te, O, Ti, I², Ti*Te, Te*I, O*I, O*Te, and O*Ti, with the interaction between OD600 nm before induction and time post-induction showing the most substantial impact on protein expression levels. Additionally, turbidity measurements using Image J and AlphaEaseFC software under predicted optimal conditions (IPTG concentration=250 μM, temperature=37°C, OD600 nm before induction=0.8, and time after induction=ON) revealed a significantly high turbidity of the protein band, indicating successful expression.

In this study, the optimization of four factors- IPTG concentration, temperature, OD600 nm before induction, and time after induction-led to a significant increase in *RfxCas13d* expression. However; potential limitations must be acknowledged and further investigation is needed to address challenges such as the scalability of the optimized conditions and potential variations in performance when using different bacterial strains.

Conclusion

This study establishes that all selected factors- IPTG concentration, temperature, OD600 nm before induction, and post-induction time- critically affect RfxCas13d expression. Applied RSM pinpointed the optimal values of these selection factors for producing recombinant *RfxCas13d*. This marks the first evaluation of the collective impact of these factors on RfxCas13d expression. Further investigation and optimization of key parameters influencing protein expression and downstream processes using RSM, along with exploring *RfxCas13d* expression in alternative host systems, will enhance our understanding of the ideal conditions for maximizing *RfxCas13d* expression.

Ethical Approval

All ethical concerns, including issues related to plagiarism, informed consent, misconduct, data fabrication and/or falsification, double publication and/or submission, and redundancy, were fully adhered to by the authors. The study's ethical procedures were sanctioned by the Ethics Committee of Hamadan University of Medical Sciences (Ethical code: IR.UMSHA.REC.1400.784). Written informed consent was also secured from all participants involved in the study. This research formed a part of Sepideh Abbaszadeh's Master of Science thesis at Hamadan University of Medical Sciences.

Acknowledgement

We extend our heartfelt gratitude to the esteemed Prof. Masoud Saeedi Jam, albeit posthumously, and to our peers at Hamadan University of Medical Sciences for their contributions.

Funding: The research received financial support from the Vice-chancellor for Research and Technology at Hamadan University of Medical Sciences, Hamadan, Iran (Grant No:1400120310208).

Conflict of Interest

The authors have no relevant financial or non-financial interests to disclose.

References

- Makarova KS, Aravind L, Wolf YI, Koonin EV. Unification of Cas protein families and a simple scenario for the origin and evolution of CRISPR-Cas systems. *Bio-logy Direct* 2011;6:38.
- Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. *Science* 2012;337(6096):816-21.
- Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, et al. Multiplex genome engineering using CRISPR/Cas systems. *Science* 2013;339(6121):819-23.
- Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, et al. RNA-guided human genome engineering via Cas9. *Science* 2013;339(6121):823-6.
- Pardee K, Green AA, Takahashi MK, Braff D, Lambert G, Lee JW, et al. Rapid, low-cost detection of Zika virus using programmable biomolecular components. *Cell* 2016;165(5):1255-66.
- Makarova KS, Haft DH, Barrangou R, Brouns SJ, Charpentier E, Horvath P, et al. Evolution and classification of the CRISPR-Cas systems. *Nat Rev Microbiol* 2011;9(6):467-77.
- Gootenberg JS, Abudayyeh OO, Lee JW, Essletzbichler P, Dy AJ, Joung J, et al. Nucleic acid detection with CRISPR-Cas13a/C2c2. *Science* 2017;356(6336):438-42.
- Heo W, Lee K, Park S, Hyun K-A, Jung H-I. Electrochemical biosensor for nucleic acid amplification-free and sensitive detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA via CRISPR/Cas13a trans-cleavage reaction. *Biosens Bioelectron* 2022;201:113960.
- Yu J, Shin J, Yu J, Kim J, Yu D, Heo WD. Programmable RNA base editing with photoactivatable CRISPR-Cas13. *Nat Commun* 2024;15(1):673.
- Huynh N, Depner N, Larson R, King-Jones K. A versatile toolkit for CRISPR-Cas13-based RNA manipulation in *Drosophila*. *Genome Biol* 2020;21(1):279.
- Makarova KS, Wolf YI, Koonin EV. Classification and nomenclature of CRISPR-Cas systems: where from here? *CRISPR J* 2018;1(5):325-36.
- Kellner MJ, Koob JG, Gootenberg JS, Abudayyeh OO, Zhang F. SHERLOCK: nucleic acid detection with CRISPR nucleases. *Nat Protoc* 2019;14(10):2986-3012.
- Sheng Y, Zhang T, Zhang S, Johnston M, Zheng X, Shan Y, et al. A CRISPR/Cas13a-powered catalytic electrochemical biosensor for successive and highly sensitive RNA diagnostics. *Biosens Bioelectron* 2021;178:113027.
- Konermann S, Lotfy P, Brideau NJ, Oki J, Shokhiev MN, Hsu PD. Transcriptome engineering with RNA-targeting type VI-D CRISPR effectors. *Cell* 2018;173(3):665-76. e14.
- Yan WX, Chong S, Zhang H, Makarova KS, Koonin EV, Cheng DR, et al. Cas13d is a compact RNA-targeting type VI CRISPR effector positively modulated by a WYL-domain-containing accessory protein. *Mol Cell* 2018;70(2):327-39. e5.
- Wei J, Lotfy P, Faizi K, Baungaard S, Gibson E, Wang E, et al. Deep learning and CRISPR-Cas13d ortholog discovery for optimized RNA targeting. *Cell Syst* 2023;14(12):1087-102. e13.
- Manoochehri H, Asadi S, Tanzadehpanah H, Sheykhasan M, Ghorbani M. CDC25A is strongly associated with colorectal cancer stem cells and poor clinical outcome of patients. *Gene Reports* 2021;25:101415.
- Sheykhasan M, Ahmadyousefi Y, Seyedebrahimi R, Tanzadehpanah H, Manoochehri H, Dama P, et al. DLX6-AS1: a putative lncRNA candidate in multiple human cancers. *Expert Rev Mol Med* 2021;23:e17.
- Soulari RN, Basafa M, Rajabibazl M, Hashemi A. Effective strategies to overcome the insolubility of recombinant ScFv antibody against EpCAM extracellular domain in *E. coli*. *International Journal of Peptide Research and Therapeutics* 2020;26(4):2465-74.
- Boyle DM, Buckley JJ, Johnson GV, Rathore A, Gustafson ME. Use of the design-of-experiments approach for the development of a refolding technology for progeniopoietin-1, a recombinant human cytokine fusion protein from *Escherichia coli* inclusion bodies. *Biotechnol Appl Biochem* 2009;54(2):85-92.
- Emamipour N, Vossoughi M, Mahboudi F, Golkar M, Fard-Esfahani P. Soluble expression of IGF1 fused to DsbA in SHuffle™ T7 strain: optimization of expression and purification by Box-Behnken design. *Appl Microbiol Biotechnol* 2019;103:3393-406.
- Aghaeepoor M, Akbarzadeh A, Kobarfard F, Shabani AA, Dehnavi E, Aval SJ, et al. Optimization and high level production of recombinant synthetic Streptokinase in *E. coli* using Response Surface Methodology. *Iran J Pharm Res* 2019;18(2):961-73.
- Ghasemi N, Bandehpour M, Ranjbari J. Optimization of key factors in serum free medium for production of human recombinant GM-CSF using response surface methodology. *I Iran J Pharm Res* 2019;18(Suppl1):146.
- Bezerra MA, Santelli RE, Oliveira EP, Villar LS, Escalera LA. Response surface methodology (RSM) as a tool for optimization in analytical chemistry. *Talanta* 2008;76(5):965-77.
- Kinna A, Tolner B, Rota EM, Titchener-Hooker N, Nesbeth D, Chester K. IMAC capture of recombinant protein from unclarified mammalian cell feed streams. *Biotechnol Bioeng* 2016;113(1):130-40.

26. Morowvat MH, Babaeipour V, Rajabi-Memari H, Vahidi H, Maghsoudi N. Overexpression of recombinant human beta interferon (rhINF- β) in periplasmic space of *Escherichia coli*. *Iran J Pharm Res* 2014;13(Suppl):151-60.
27. Papaneophytou CP, Kontopidis G. Statistical approaches to maximize recombinant protein expression in *Escherichia coli*: a general review. *Protein Expr Purif* 2014;94:22-32.
28. Rostami N, Goharrizi LY. Cloning, expression, and purification of the human synthetic survivin protein in *Escherichia coli* using response surface methodology (RSM). *Mol Biotechnol* 2023;65(3):326-36.
29. Sambrook J. *Molecular cloning: A laboratory manual*, Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press. 9. (No Title). 1989;14:23.
30. Chen W-H, Uribe MC, Kwon EE, Lin K-YA, Park Y-K, Ding L, et al. A comprehensive review of thermoelectric generation optimization by statistical approach: Taguchi method, analysis of variance (ANOVA), and response surface methodology (RSM). *Renewable and Sustainable Energy Reviews* 2022;169:112917.
31. He F. Bradford protein assay. *Bio-protocol* 2011:e45-e.
32. Hernandez-Huertas L, Kushawah G, Diaz-Moscoso A, Tomas-Gallardo L, Moreno-Sanchez I, da Silva Pescador G, et al. Optimized CRISPR-RfxCas13d system for RNA targeting in zebrafish embryos. *STAR Protoc* 2022;3(1):101058.
33. Kushawah G, Hernandez-Huertas L, Del Prado JA-N, Martinez-Morales JR, DeVore ML, Hassan H, et al. CRISPR-Cas13d induces efficient mRNA knockdown in animal embryos. *Dev Cell* 2020;54(6):805-17. e7.
34. Tegel H, Tourle S, Ottosson J, Persson A. Increased levels of recombinant human proteins with the *Escherichia coli* strain Rosetta (DE3). *Protein Expr Purif* 2010;69(2):159-67.
35. Yousefi M, Farajnia S, Mokhtarzadeh A, Akbari B, Khosroshahi SA, Mamipour M, et al. Soluble expression of humanized anti-CD20 single chain antibody in *Escherichia coli* by cytoplasmic chaperones co-expression. *Avicenna J Med Biotechnol* 2018;10(3):141-6.
36. Breig SJM, Luti KJK. Response surface methodology: A review on its applications and challenges in microbial cultures. *Materials Today: Proceedings* 2021;42:2277-84.
37. Chelladurai SJS, Murugan K, Ray AP, Upadhyaya M, Narasimharaj V, Gnanasekaran S. Optimization of process parameters using response surface methodology: A review. *Materials Today: Proceedings* 2021;37:1301-4.
38. Weremfo A, Abassah-Oppong S, Adulley F, Dabie K, Seidu-Larry S. Response surface methodology as a tool to optimize the extraction of bioactive compounds from plant sources. *J Sci Food Agric* 2023;103(1):26-36.
39. Francis DM, Page R. Strategies to optimize protein expression in *E. coli*. *Curr Protoc Protein Sci* 2010;61(1):5.24.1-5.24.29.
40. Choi JH, Keum KC, Lee SY. Production of recombinant proteins by high cell density culture of *Escherichia coli*. *Chemical Engineering Science* 2006;61(3):876-85.